Table 2.
Comparison of clinical characteristics between the increased and non-increased retinal haemorrhage groups in branch retinal vein occlusion patients.
| Parameters | Increased group (n = 22) | Non-increased group (n = 46) | P value |
|---|---|---|---|
| Area, superior, n (%) | 13 (59.1%) | 38 (82.6%) | 0.070 |
| Type of BRVO, ischaemic type, n (%) | 12 (54.5%) | 7 (15.2%) | 0.001* |
| Type of BRVO, macular, n (%) | 5 (22.7%) | 16 (34.8%) | 0.405 |
| Initial therapy, bevacizumab, n (%) | 19 (86.4%) | 41 (89.1%) | 0.707 |
| Total follow-up period, months, mean (SD) | 14 (3) | 13 (3) | 0.137 |
| Total number of intravitreal injections, mean (SD) | 4 (1) | 3 (1) | 0.093 |
| Baseline best corrected visual acuity, logMAR (SD) | 0.71 (0.25) | 0.60 (0.33) | 0.158 |
| Baseline intraocular pressure, mmHg, mean (SD) | 14.36 (2.63) | 13.72 (2.15) | 0.285 |
| Baseline spherical equivalent, mean (SD) | 1.19 (0.74) | 1.82 (2.44) | 0.146 |
| Baseline central subfield macular thickness, μm, mean (SD) | 512.95 (103.40) | 445.43 (134.05) | 0.041* |
| Baseline subchoroidal thickness, μm, mean (SD) | 203.86 (82.09) | 244.22 (105.05) | 0.120 |
| Occlusion distance from optic disc margin, μm, mean (SD) | 794.41 (521.21) | 1,134.17 (703.27) | 0.048* |
BRVO branch retinal vein occlusion.
*Statistically significant as calculated using independent two-samples t test or Pearson’s chi square test.